MiR-22/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinoma

43Citations
Citations of this article
31Readers
Mendeley users who have this article in their library.

Abstract

Background: Tongue squamous cell carcinoma (TSCC) is the most common oral cancer. Neoadjuvant systemic treatment before or after surgery for advanced TSCC is considered one of the most crucial factors in reducing mortality. However, the therapeutic benefits of chemotherapy are usually attenuated due to intrinsic and/or acquired drug resistance, and a large proportion of TSCC are resistant to chemotherapy, which may result in more aggressive tumor behavior and an even worse clinical outcome. Recently, the potential application of using miRNAs to predict therapeutic response to cancer treatment holds high promise, but miRNAs with predictive value remain to be identified and underlying mechanisms remain to be understood in TSCC. Methods: The expression of miR-22 in tissues from patients diagnosed with TSCC was analyzed using real-time PCR. The effects of miR-22 on cell proliferation and tumorigenesis in TSCC cells were analyzed by MTS assay, and flow cytometry. The tumor growth in vivo was observed in xenograft model. Luciferase reporter assay, real-time PCR and western blot were performed to validate a potential target of miR-22 in TC. The correlation between miR-22 expression and KAT6B expression, as well as the mechanisms by which miR-22 regulates PI3k-Akt-NF-kB pathway in TSCC were also addressed. Results: We found a strong correlation between miR-22 expression and chemosensitivity to cisplatin (CDDP) in TSCC patients. Ectopic overexpression of miR-22 enhanced TSCC cells apoptosis in response to CDDP in experimental models performed in vitro and in vivo. Moreover, we found that KAT6B is a direct functional target of miR-22. Ectopic expression of KAT6B attenuated the efficiency of miR-22 in TSCC cells upon CDDP treatment. Mechanistically, miR-22 overexpression or KAT6B knockdown inhibited PI3K/Akt/NF-κB signaling in TSCC cells, possibly via downregulating the activators of PI3K/Akt/NF-κB signaling, such as S100A8, PDGF and VEGF. Furthermore, the activation of miR-22 depended on the intensity of the stresses in the presence of p53 activation. Conclusions: Our findings define miR-22 as an intrinsic molecular switch that determines p53-dependent cellular fate through KAT6B/ PI3K-Akt/ NF-kB pathway.

References Powered by Scopus

Cancer statistics in China, 2015

16879Citations
N/AReaders
Get full text

Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths

3919Citations
N/AReaders
Get full text

Causes and consequences of microRNA dysregulation in cancer

2752Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Regulation of Nuclear Factor-KappaB (NF-κB) signaling pathway by non-coding RNAs in cancer: Inhibiting or promoting carcinogenesis?

195Citations
N/AReaders
Get full text

Quercetin suppresses the tumorigenesis of oral squamous cell carcinoma by regulating microRNA-22/WNT1/β-catenin axis

65Citations
N/AReaders
Get full text

The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology

60Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Gu, Y., Liu, H., Kong, F., Ye, J., Jia, X., Zhang, Z., … He, Z. (2018). MiR-22/KAT6B axis is a chemotherapeutic determiner via regulation of PI3k-Akt-NF-kB pathway in tongue squamous cell carcinoma. Journal of Experimental and Clinical Cancer Research, 37(1). https://doi.org/10.1186/s13046-018-0834-z

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

65%

Researcher 5

29%

Professor / Associate Prof. 1

6%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 6

35%

Medicine and Dentistry 5

29%

Agricultural and Biological Sciences 4

24%

Nursing and Health Professions 2

12%

Save time finding and organizing research with Mendeley

Sign up for free